Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30717403 | 0.99 | GRM5 (0.44) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717497 | 0.98 | GRM5 (0.45) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717555 | 0.97 | GRM5 (0.44) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717321 | 0.92 | GRM5 (0.42) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717493 | 0.92 | ADORA2A (0.45) | GRM5ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL30717410 | 0.91 | GRM5 (0.56) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717394 | 0.90 | ADORA2A (0.39) | GRM5ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL30717481 | 0.89 | GRM5 (0.44) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717366 | 0.88 | GRM5 (0.41) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717326 | 0.87 | GRM5 (0.44) | GRM5ADORA2AADORA1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | claimed |
| WO-2024038128-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | claimed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038128-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | GRM5 2029/4885ADORA2A 67/4885ADORA1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.